000292542 001__ 292542
000292542 005__ 20241029144012.0
000292542 0247_ $$2doi$$a10.3390/jpm14080818
000292542 0247_ $$2pmid$$apmid:39202010
000292542 0247_ $$2pmc$$apmc:PMC11355119
000292542 037__ $$aDKFZ-2024-01785
000292542 041__ $$aEnglish
000292542 082__ $$a610
000292542 1001_ $$0P:(DE-He78)3cb0e3df380b462dd19c8f931cd090d4$$ade Vrieze, Maxime$$b0$$eFirst author$$udkfz
000292542 245__ $$aProstate Cancer Screening in Young Men.
000292542 260__ $$aBasel$$bMDPI$$c2024
000292542 3367_ $$2DRIVER$$aarticle
000292542 3367_ $$2DataCite$$aOutput Types/Journal article
000292542 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1725629000_31211$$xReview Article
000292542 3367_ $$2BibTeX$$aARTICLE
000292542 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000292542 3367_ $$00$$2EndNote$$aJournal Article
000292542 500__ $$a#EA:C130#LA:C130#
000292542 520__ $$aBackground: Prostate cancer (PCa) screening strategies are being developed and evaluated in several countries. However, most of the evidence regarding PCa screening has been generated in study populations aged 50 and older. Aims: This study summarizes findings of a screening trial in younger men and discuss those findings in the context of other screening trials. Methods: Non-systematic review. Results: Screening of 45-year-old men resulted in a low PCa detection rate. Nonetheless, almost 70% of screen-detected PCa at this age was clinically significant. In young men ISUP GG 1 screen-detected cancers warrant rigorous follow-up. A baseline, midlife prostate-specific antigen (PSA) value at age 45 may safely exclude the vast majority of men from further screening investigations for at least 5 years. At age 45, a confirmatory PSA value reduces the number of subsequent tests almost by half. Sequential magnetic resonance imaging (MRI) as a reflex test subsequent to an elevated PSA ≥ 3 ng/mL needs further investigation in young men. Conclusions: Screening in young men needs to be carefully investigated in order to avoid overscreening and overdiagnosis.
000292542 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000292542 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000292542 650_7 $$2Other$$aPSA
000292542 650_7 $$2Other$$abaseline PSA
000292542 650_7 $$2Other$$amultiparametric MRI
000292542 650_7 $$2Other$$aprostate cancer
000292542 650_7 $$2Other$$aprostate cancer screening
000292542 650_7 $$2Other$$arisk-adapted screening
000292542 7001_ $$0P:(DE-He78)555d0aa06e51f29f46d788ff54fc6811$$aAl-Monajjed, Rouvier$$b1$$udkfz
000292542 7001_ $$00000-0002-1522-6374$$aBoschheidgen, Matthias$$b2
000292542 7001_ $$0P:(DE-He78)f84639cbc39bc20ecda8d00e6de97578$$aAlbers, Peter$$b3$$eLast author$$udkfz
000292542 773__ $$0PERI:(DE-600)2662248-8$$a10.3390/jpm14080818$$gVol. 14, no. 8, p. 818 -$$n8$$p818$$tJournal of Personalized Medicine$$v14$$x2075-4426$$y2024
000292542 8564_ $$uhttps://inrepo02.dkfz.de/record/292542/files/jpm-14-00818.pdf
000292542 8564_ $$uhttps://inrepo02.dkfz.de/record/292542/files/jpm-14-00818.pdf?subformat=pdfa$$xpdfa
000292542 909CO $$ooai:inrepo02.dkfz.de:292542$$pVDB
000292542 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3cb0e3df380b462dd19c8f931cd090d4$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000292542 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)555d0aa06e51f29f46d788ff54fc6811$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000292542 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f84639cbc39bc20ecda8d00e6de97578$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000292542 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000292542 9141_ $$y2024
000292542 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-29
000292542 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-29
000292542 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-29
000292542 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-04-12T15:01:05Z
000292542 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-04-12T15:01:05Z
000292542 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-04-12T15:01:05Z
000292542 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2023-04-12T15:01:05Z
000292542 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-29
000292542 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-29
000292542 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-29
000292542 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-29
000292542 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-29
000292542 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-29
000292542 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-29
000292542 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-08-29
000292542 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-08-29
000292542 9202_ $$0I:(DE-He78)C130-20160331$$kC130$$lPersonalisierte Früherkennung des Prostatakarzinoms$$x0
000292542 9201_ $$0I:(DE-He78)C130-20160331$$kC130$$lPersonalisierte Früherkennung des Prostatakarzinoms$$x0
000292542 9200_ $$0I:(DE-He78)C130-20160331$$kC130$$lPersonalisierte Früherkennung des Prostatakarzinoms$$x0
000292542 980__ $$ajournal
000292542 980__ $$aVDB
000292542 980__ $$aI:(DE-He78)C130-20160331
000292542 980__ $$aUNRESTRICTED